A Phase 2b, Randomized, Blinded Trial Investigating the Efficacy and Safety of Visugromab in Combination With Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Participants With Unresectable or Metastatic Hepatocellular Carcinoma and Compensated Liver Function (Child-Pugh A) After Failure of First-Line Treatment That Included an Approved Anti PD-(L)1 Compound (GDFATHER HCC-01)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT07219459

Title field or adapter rule

protocolSection.identificationModule.officialTitle

Ingested At

2026-04-28T10:41:25.508892+00:00

Published At

2026-04-27T00:00:00+00:00

Record Updated At

2026-04-27

Timestamp Basis

source retrieval time was not retained by the feed adapter

Date limitation

source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Unresectable or Metastatic Hepatocellular Carcinoma", "Child-Pugh A Hepatocellular Carcinoma", "Failure of First-Line Treatment That Included an Approved Anti PD-(L)1 Compound"]

protocolSection.statusModule.lastUpdatePostDateStruct.date

"2026-04-27"

protocolSection.identificationModule.nctId

"NCT07219459"

protocolSection.identificationModule.officialTitle

"A Phase 2b, Randomized, Blinded Trial Investigating the Efficacy and Safety of Visugromab in Combination With Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Participants With Unresectable or Metastatic Hepatocellular Carcinoma and Compensated Liver Function (Child-Pugh A) After Failure of First-Line Treatment That Included an Approved Anti PD-(L)1 Compound (GDFATHER HCC-01)"

protocolSection.statusModule.overallStatus

"RECRUITING"

protocolSection.designModule.phases

["PHASE2"]

protocolSection.statusModule.resultsFirstPostDateStruct.date

""

Study condition terms

• Unresectable or Metastatic Hepatocellular Carcinoma (protocolSection.conditionsModule.conditions)
• Child-Pugh A Hepatocellular Carcinoma (protocolSection.conditionsModule.conditions)
• Failure of First-Line Treatment That Included an Approved Anti PD-(L)1 Compound (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.